<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562132</url>
  </required_header>
  <id_info>
    <org_study_id>R21NS077858-01</org_study_id>
    <secondary_id>R21NS077858-01</secondary_id>
    <nct_id>NCT01562132</nct_id>
  </id_info>
  <brief_title>Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection</brief_title>
  <acronym>SToP-Crypto</acronym>
  <official_title>An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with two medicines in combination
      (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for
      the treatment of an early infection with a fungus called cryptococcus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there is wide variation in practice and little evidence to guide the treatment of
      early cryptococcal infection in HIV-infected individuals with advanced immunosuppression.
      However, epidemiologic studies suggest that this may be a promising novel approach to
      decrease the mortality due to cryptococcal meningitis (CM), the second leading cause of death
      among HIV-infected individuals in many resource-limited settings. Screening asymptomatic
      HIV-infected individuals with advanced immunosuppression for serum cryptococcal antigen
      (CrAg) clearly identifies a population at high risk of CM and death and is a feasible
      screening method for resource-limited settings. However, screening with serum CrAg alone
      without additional diagnostic studies identifies a heterogeneous clinical population with
      early cryptococcal infection, many of whom already have sub-clinical meningeal infection or
      fungemia. The mainstay of anti-cryptococcal therapy in resource-limited settings is oral
      fluconazole though preliminary evidence suggests this is not an effective treatment. Thus,
      there is a critical need for potent therapies that (1) can be safely administered in
      resource-limited settings and (2) are effective in a heterogeneous population of HIV-infected
      individuals with advanced immunosuppression and early cryptococcal infection who are
      initiating anti-retroviral therapy (ART).

      This single center, open-label, randomized Phase IIb study is being conducted to assess the
      safety and estimate the efficacy of oral fluconazole in combination with flucytosine for the
      treatment of early cryptococcal infection. The study will be based at two sites supported by
      Family AIDS Care and Education Services (FACES) in Western Kenya. A consecutive sample of 100
      HIV-infected adults with CD4 cell count ≤100 cells/µl and serum CrAg titer ≥1:2 who have no
      signs or symptoms of severe, systemic cryptococcal infection will be enrolled. At enrollment,
      specimens from participants will be cultured for evidence of Cryptococcus neoformans.
      Individuals who meet inclusion and exclusion criteria and consent to participate in the study
      will be randomized to combination therapy with oral fluconazole (1200mg/day) plus flucytosine
      (100mg/kg/day) or fluconazole alone for the fourteen days of therapy. Subsequently both
      groups will receive anti-retroviral therapy as well as fluconazole 800mg/day for 8 weeks
      followed by 200mg/day. The primary safety endpoint will be the incidence of treatment-related
      adverse events and serious adverse events. The primary efficacy endpoint will be survival at
      12 weeks.

      In addition, we will offer additional diagnostic testing and aim for 50% participation,
      approximately 25 individuals from each arm. We will perform a battery of diagnostic tests
      including chest radiography, fungal cultures in blood, sputum, urine, stool and cerebrospinal
      fluid (CSF), cryptococcal antigen testing in the CSF, and gram stain, Ziehls-Nielsen stain
      and India Ink staining of CSF sediment. Anti-fungal susceptibility testing via broth
      microdilution and polymerase chain reaction serotyping and mating type analysis will be
      performed on clinical isolates.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped in accordance with pre-specified stopping rules for poor recruitment.
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival at 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Individuals Who Develop Cryptococcal Meningitis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF.
Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Individuals Who Develop Immune Reconstitution Inflammatory Syndrome Due to Cryptococcus</measure>
    <time_frame>24 weeks</time_frame>
    <description>Individuals who develop clinical meningitis without evidence of fungal, bacterial, or parasitic (e.g. malaria) organisms in the cerebrospinal fluid. Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieve Targeted Recruitment, Retention and Adherence Rates</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Individuals Requiring Treatment Discontinuation</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Individuals Requiring Dose Reduction</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Individuals With Treatment Related Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Individuals With Treatment Related Serious Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cryptococcal Meningitis-free Survival at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF.
Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cryptococcal Infection Disseminated</condition>
  <arm_group>
    <arm_group_label>5FC plus fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with oral fluconazole and flucytosine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluconazole alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluconazole monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucytosine and fluconazole</intervention_name>
    <description>Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
    <arm_group_label>5FC plus fluconazole</arm_group_label>
    <other_name>Ancobon</other_name>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
    <arm_group_label>fluconazole alone</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to give informed consent

          -  Age &gt; 18 years

          -  HIV infection as confirmed by HIV-antibody test as per Kenyan guidelines

          -  CD4+ T-cell count ≤100 cells/µl

          -  Serum CrAg titer≥1:2

          -  Able to travel to district hubs (Sindo District Hospital, Lumumba Health Centre) for
             regular study visits

        Exclusion Criteria:

          -  clinical meningitis:

          -  clinical sepsis:

          -  hemiparesis, aphasia, visual field deficit or other finding on neurological
             examination localizable to the central nervous system

          -  a history of culture proven or suspected (cryptococcal antigen present) cryptococcal
             meningitis

          -  a history of stroke or other infection of the central nervous system

          -  a seizure within the last 2 months

          -  currently taking or ever taken antiretroviral therapy

          -  currently taking anti-tuberculous therapy

          -  currently or recently (&lt;2 months) prescribed fluconazole, itraconazole, clotrimazole
             troches, amphotericin or other oral anti-fungal medications

          -  pregnant or breast-feeding

          -  alanine aminotransferase concentration more than 3 times the upper limit of normal

          -  neutrophil count &lt;1000x103 cells/mL

          -  hemoglobin &lt;8g/dL

          -  platelet count &lt;100,000x 103 platelets/mL

          -  creatinine clearance ≤50 ml/min

          -  individuals with active heavy alcohol use or active recreational drug use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana-Claire L Meyer, MD, MSHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith K Kwasa, MBChB MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nairobi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Family AIDS Care and Education Services</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family AIDS Care and Education Services</name>
      <address>
        <city>Sindo</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <results_first_submitted>July 31, 2015</results_first_submitted>
  <results_first_submitted_qc>July 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2015</results_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Ana-Claire Meyer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cryptococcus</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5FC Plus Fluconazole</title>
          <description>Combination therapy with oral fluconazole and flucytosine
Flucytosine and fluconazole: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
        <group group_id="P2">
          <title>Fluconazole Alone</title>
          <description>Fluconazole monotherapy
Fluconazole: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5FC Plus Fluconazole</title>
          <description>Combination therapy with oral fluconazole and flucytosine
Flucytosine and fluconazole: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
        <group group_id="B2">
          <title>Fluconazole Alone</title>
          <description>Fluconazole monotherapy
Fluconazole: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="28" upper_limit="49"/>
                    <measurement group_id="B2" value="31" lower_limit="26" upper_limit="58"/>
                    <measurement group_id="B3" value="33.5" lower_limit="26" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell Count</title>
          <units>cells/microliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="18" upper_limit="56"/>
                    <measurement group_id="B2" value="13" lower_limit="3" upper_limit="16"/>
                    <measurement group_id="B3" value="17" lower_limit="3" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival at 12 Weeks</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5FC Plus Fluconazole</title>
            <description>Combination therapy with oral fluconazole and flucytosine
Flucytosine and fluconazole: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole Alone</title>
            <description>Fluconazole monotherapy
Fluconazole: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at 12 Weeks</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival at 2 Weeks</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival at 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Individuals Who Develop Cryptococcal Meningitis</title>
        <description>Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF.
Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Individuals Who Develop Immune Reconstitution Inflammatory Syndrome Due to Cryptococcus</title>
        <description>Individuals who develop clinical meningitis without evidence of fungal, bacterial, or parasitic (e.g. malaria) organisms in the cerebrospinal fluid. Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achieve Targeted Recruitment, Retention and Adherence Rates</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Individuals Requiring Treatment Discontinuation</title>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Individuals Requiring Dose Reduction</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Individuals With Treatment Related Adverse Events</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Individuals With Treatment Related Serious Adverse Events</title>
        <time_frame>24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cryptococcal Meningitis-free Survival at 24 Weeks</title>
        <description>Clinical meningitis AND at least one of the following: cryptococcal antigen in the cerebrospinal fluid (CSF), cryptococcal organisms on India Ink stain, or fungal culture of CSF.
Clinical meningitis will be defined as:
fever&gt;39.0°C, AND
severe headache, AND
At least one of the following:
meningismus,
photophobia,
new onset seizure,
focal neurological deficit localizable to the central nervous system
papilledema
confusion, delirium, or decreased level of consciousness.</description>
        <time_frame>24 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>5FC Plus Fluconazole</title>
          <description>Combination therapy with oral fluconazole and flucytosine
Flucytosine and fluconazole: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
        <group group_id="E2">
          <title>Fluconazole Alone</title>
          <description>Fluconazole monotherapy
Fluconazole: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unintentional Weight Loss</sub_title>
                <description>Grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ana-Claire Meyer</name_or_title>
      <organization>Yale University</organization>
      <phone>203-737-8372</phone>
      <email>ana-claire.meyer@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

